Drug · Small Molecule

Mocetinostat

CI-DRUG-00000383Explore in graph →NCIt C62521 CHEMBL272980 CIViC Phase 2

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	2	18	—	—	2004-04
Malignant Lung Neoplasm	Phase2	Phase 2	1	2	—	—	Nov 7, 2016
Hodgkin Lymphoma	Phase2	Phase 2	0	1	—	—	2006-08
Leukemia	Phase2	Phase 2	0	6	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HDAC2 Overexpression1
Mocetinostat	Malignant Breast Neoplasm

Clinical trials

Trials with this intervention (18)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–18 of 18 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03220477	Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.	active not recruiting	Phase 1	28	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 5, 2026	clinicaltrials
NCT04299113	Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Molecule

Record

Kind: Small Molecule
Mechanism: Histone deacetylase 1 inhibitor; Histone deacetylase 2 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 11 inhibitor; Histone deacetylase 8 inhibitor
Targets: 5 genes
Aliases: Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-, MG-0103, MGCD 0103, MGCD-0103, MGCD0103, Mocetinostat, N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide

Data updated 6 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.